11 min listen
ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
13 minutes
Released:
Sep 14, 2021
Format:
Podcast episode
Description
In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.
Released:
Sep 14, 2021
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: STRENGTH Trial: High-Dose Omega-3 Fatty Acids vs. Corn Oil: The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research